Special Issue "Neuromodulating Bioactive Cerebral Pathways as Potential Cognitive Therapeutics"
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 212
Special Issue Editors
Interests: cognitive disorders; stroke; neurodegenerative diseases; behavior; pharmacology
Interests: cognitive disorders; behavior; neurophysiology; neuroimaging; pharmacology
Special Issues, Collections and Topics in MDPI journals
Interests: cognition; behavior; animal models; neurotransmission; pharmacology
Special Issue Information
Dear Colleagues,
Due to the ageing population and the development of mental illnesses linked to mutations in society, the question of cognitive disorders holds a major stake in the next decades. Even if there have been many disappointments in the past, the pharmacological approach to cognitive disorders remains an unavoidable option for the multimodal treatment of cognitive disorders.
The numerous bioactive molecular pathways that underlie the different cognitive functions constitute many pharmacological targets. Of course, neurotransmission pathways remain important, but other pathways are emerging, such as hormones, neuropeptides, growth factors, transduction pathways, and steroids. The pathways involved in the processes leading to neurodegeneration or dysconnectivity, whether specific or not, remain relevant for pharmacological modulation.
The aim of this Special Issue is to review the advances in the pharmacological modulation of bioactive brain pathways for the treatment of cognitive disorders. It will include original articles, reviews of the literature, and methodological developments in both experimental and clinical approaches.
Prof. Dr. Régis Bordet
Dr. Thibaut Dondaine
Dr. Julie Deguil
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cognitive disorders
- neurotransmission
- hormones
- neuropeptides
- neurodegeneration
- dysconnectivity
- inflammation
- transduction
- drugs
- models
- trial
